BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now
Advanced Search

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

15 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.EBI
Integral Biosciences
SAH derived potent and selective EZH2 inhibitors.EBI
Pfizer
Recent advances in EZH2-based dual inhibitors in the treatment of cancers.EBI
Xinxiang University
A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.EBI
China Pharmaceutical University
Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.EBI
Sichuan University
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).EBI
"Sapienza" University of Rome
Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.EBI
Affiliated Hospital of Guangdong Medical University
Targeting EZH2 for cancer therapy: From current progress to novel strategies.EBI
West China Hospital
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2.EBI
Sichuan University
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LympEBI
Constellation Pharmaceuticals
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.EBI
Northwestern University
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.EBI
China Pharmaceutical University
Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.EBI
Icahn School of Medicine At Mount Sinai
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinEBI
Wuxi Apptec